The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inh...

Source: Trials - March 7, 2018 Category: General Medicine Authors: Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger Owen, Mark Cook and Gordon Cook Tags: Study protocol Source Type: research